NVZMF (Novonesis (Novozymes) B) Issuance of Debt: $3,947 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVZMF Novonesis (Novozymes) B NVZMF
89 GF Score
Price $66.56
GF Value $64.13
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Issuance of Debt?

Novonesis (Novozymes) B NVZMF +2.95% 89 Issuance of Debt is $3,947 Mil as of Mar. 2026. GuruFocus rates NVZMF with a GF Score™ of 89/100 and a GF Value™ of $64.13 (Fairly Valued). The stock has 3 warning signs investors should review.

Novonesis (Novozymes) B's Issuance of Debt for the three months ended in Mar. 2026 was $1,997 Mil.

Novonesis (Novozymes) B's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $3,947 Mil.

Novonesis (Novozymes) B Issuance of Debt Related Terms

Novonesis (Novozymes) B Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Issuance of Debt Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 373.29 331.69 482.01 140.84 2,009.95

Novonesis (Novozymes) B Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.76 1,926.30 0.00 23.19 1,997.23
NVZMF
89GF Score
Novonesis (Novozymes) B NVZMF
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,947 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $3,947 Mil mean?
Novonesis (Novozymes) B (NVZMF) has a Issuance of Debt of $3,947 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Novonesis (Novozymes) B and its competitors.
Is Novonesis (Novozymes) B's Issuance of Debt too high?
Novonesis (Novozymes) B's current Issuance of Debt is $3,947 Mil. Overall, Novonesis (Novozymes) B has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Issuance of Debt compare to LIN and SHW?
Novonesis (Novozymes) B's Issuance of Debt of $3,947 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Chemicals company?
A good Issuance of Debt depends on the Chemicals industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Novonesis (Novozymes) B and its competitors. Novonesis (Novozymes) B's current Issuance of Debt is $3,947 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (NVZMF) is currently considered Fairly Valued. The stock's GF Value™ is $64.13, compared to a current price of $66.56 — trading 3.8% above its estimated fair value. The current Issuance of Debt is $3,947 Mil. Novonesis (Novozymes) B's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Novonesis (Novozymes) B (NVZMF), the current Issuance of Debt is $3,947 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (NVZMF) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued. The current stock price of $66.56 is trading 3.8% above its estimated GF Value™ of $64.13. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for NVZMF:

  • Issuance of Debt: $3,947 Mil
  • GF Value™: $64.13 vs. price of $66.56 (3.8% above fair value)
  • GF Score™: 89/100 with 3 warning signs

No single metric tells the full story. See the NVZMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
89GF Score

Get the complete analysis for NVZMF

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$66.56
Price
$64.13
GF Value